Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
ECTE's Cash to Debt is ranked higher than
89% of the 1152 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. ECTE: No Debt )
ECTE' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: No Debt

Equity to Asset 0.76
ECTE's Equity to Asset is ranked higher than
84% of the 1034 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. ECTE: 0.76 )
ECTE' s 10-Year Equity to Asset Range
Min: 0.23   Max: 0.91
Current: 0.76

0.23
0.91
F-Score: 4
Z-Score: -13.72
M-Score: -3.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -72464.71
ECTE's Operating margin (%) is ranked lower than
58% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. ECTE: -72464.71 )
ECTE' s 10-Year Operating margin (%) Range
Min: -300800   Max: 11.11
Current: -72464.71

-300800
11.11
Net-margin (%) -88011.76
ECTE's Net-margin (%) is ranked lower than
58% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.10 vs. ECTE: -88011.76 )
ECTE' s 10-Year Net-margin (%) Range
Min: -246640   Max: -1.41
Current: -88011.76

-246640
-1.41
ROE (%) -96.92
ECTE's ROE (%) is ranked lower than
55% of the 1129 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.93 vs. ECTE: -96.92 )
ECTE' s 10-Year ROE (%) Range
Min: -251.11   Max: 1.95
Current: -96.92

-251.11
1.95
ROA (%) -82.10
ECTE's ROA (%) is ranked lower than
56% of the 1161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.32 vs. ECTE: -82.10 )
ECTE' s 10-Year ROA (%) Range
Min: -241.42   Max: 0.93
Current: -82.1

-241.42
0.93
ROC (Joel Greenblatt) (%) -785.55
ECTE's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 1156 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.14 vs. ECTE: -785.55 )
ECTE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9177.57   Max: 27.45
Current: -785.55

-9177.57
27.45
Revenue Growth (3Y)(%) -100.00
ECTE's Revenue Growth (3Y)(%) is ranked lower than
55% of the 932 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. ECTE: -100.00 )
ECTE' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 44.2
Current: -100

0
44.2
EBITDA Growth (3Y)(%) -32.70
ECTE's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 839 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. ECTE: -32.70 )
ECTE' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -53.4   Max: 14.6
Current: -32.7

-53.4
14.6
EPS Growth (3Y)(%) -36.70
ECTE's EPS Growth (3Y)(%) is ranked higher than
54% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. ECTE: -36.70 )
ECTE' s 10-Year EPS Growth (3Y)(%) Range
Min: -49.2   Max: 1644.6
Current: -36.7

-49.2
1644.6
» ECTE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ECTE Guru Trades in Q1 2014

Jim Simons 40,787 sh (-64.62%)
» More
Q2 2014

ECTE Guru Trades in Q2 2014

Jim Simons Sold Out
» More
Q3 2014

ECTE Guru Trades in Q3 2014

Jim Simons 10,100 sh (New)
» More
Q4 2014

ECTE Guru Trades in Q4 2014

Jim Simons 22,400 sh (+121.78%)
» More
» Details

Insider Trades

Latest Guru Trades with ECTE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.40
ECTE's P/B is ranked higher than
79% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. ECTE: 2.40 )
ECTE' s 10-Year P/B Range
Min: 0.24   Max: 30.39
Current: 2.4

0.24
30.39
P/S 395.09
ECTE's P/S is ranked lower than
74% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. ECTE: 395.09 )
ECTE' s 10-Year P/S Range
Min: 7.58   Max: 2622.22
Current: 395.09

7.58
2622.22
Current Ratio 0.61
ECTE's Current Ratio is ranked lower than
56% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. ECTE: 0.61 )
ECTE' s 10-Year Current Ratio Range
Min: 0.08   Max: 10.69
Current: 0.61

0.08
10.69
Quick Ratio 0.61
ECTE's Quick Ratio is ranked lower than
53% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. ECTE: 0.61 )
ECTE' s 10-Year Quick Ratio Range
Min: 0.08   Max: 10.69
Current: 0.61

0.08
10.69

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -64.50
ECTE's Earnings Yield (Greenblatt) is ranked lower than
64% of the 1148 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. ECTE: -64.50 )
ECTE' s 10-Year Earnings Yield (Greenblatt) Range
Min: -67.4   Max: 4882.5
Current: -64.5

-67.4
4882.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:XS5B.Germany,
Echo Therapeutics Inc was incorporated in Delaware in September 2007 under the name Durham Pharmaceuticals Acquisition Co. It is a medical device company with expertise in advanced skin permeation technology. The Companys medical device program is Symphony, a non-invasive, wireless, continuous glucose monitoring system designed to provide reliable, real-time glucose data conveniently, continuously and cost-effectively. The Symphony CGM System incorporates its SkinPrep device, transdermal glucose sensor, wireless transmitter and data display monitor. It is developing its Prelude SkinPrep System as a platform technology to allow for enhanced skin permeation that will enable two important applications; analyte extraction and needle-free drug delivery. It currently has two key strategic partnerships in place. It has granted Ferndale Pharma Group, Inc. a license to develop, market and sell the Prelude device for enhanced and needle-free delivery of topical anesthetics prior to needle insertion. It has also granted Handok Pharmaceuticals Co., Ltd. a license to develop, market and sell the Symphony CGM System for continuous glucose monitoring in South Korea. The Company competes with Edwards Lifesciences Corporation, Optiscan Biomedical Corp., Maquet Critical Care AB, Medtronic, Inc. A. Menarini Diagnostics S.r.l., Roche, Johnson & Johnson, Bayer and Abbott Laboratories. Government authorities in the United States, at the federal, state and local level, the European Union, and other countries extensively regulate the research, development, testing, manufacture, labeling, promotion, advertising, distribution, marketing, export and import of products such as those the Company are developing.
» More Articles for ECTE

Headlines

Articles On GuruFocus.com
5 Healthcare Picks for 2012 Mar 21 2012 

More From Other Websites
ECHO THERAPEUTICS, INC. Financials Apr 24 2015
10-K for Echo Therapeutics, Inc. Apr 22 2015
ECHO THERAPEUTICS, INC. Files SEC form 10-Q/A, Quarterly Report Apr 20 2015
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 16 2015
Echo Therapeutics, Inc. Announces 2014 Financial Results Apr 15 2015
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or Interim... Apr 15 2015
Echo Therapeutics, Inc. Announces 2014 Financial Results Apr 15 2015
Echo Therapeutics, Inc. Achieves Wireless Mobile Communication Milestone Mar 30 2015
Echo Therapeutics, Inc. Achieves Wireless Mobile Communication Milestone Mar 30 2015
Echo Therapeutics Announces Conference Call and Webcast to Provide Corporate Update Feb 23 2015
Echo Therapeutics Announces Conference Call and Webcast to Provide Corporate Update Feb 23 2015
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered... Feb 18 2015
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant Feb 05 2015
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Feb 04 2015
Echo Therapeutics Restores Pact with MTIA, Issues Patent - Analyst Blog Jan 22 2015
Echo Therapeutics and Medical Technologies Innovation Asia (MTIA) Re-affirm Operational Partnership Jan 21 2015
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 06 2015
Echo Therapeutics Re-hires Key Product Development Team In Support of New Corporate Strategy Jan 06 2015
Echo Therapeutics Re-hires Key Product Development Team In Support of New Corporate Strategy Jan 06 2015
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Dec 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK